01531nas a2200361   4500000000100000008004100001260000900042653001500051653001000066653000900076653001600085653001200101653003300113653002200146653003000168653001100198653001400209653001100223653001200234653000900246653001600255653001200271653002300283653001300306100001600319700001400335700001400349245013000363300000900493490000700502520064600509022001401155       1988                            d  c198810aAdolescent10aAdult10aAged10aClofazimine10aDapsone10aDrug Administration Schedule10aDrug Interactions10aDrug Therapy, Combination10aFemale10aHalf-Life10aHumans10aleprosy10aMale10aMiddle Aged10aNigeria10aPatient Compliance10aRifampin1 aPieters F A1 aWoonink F1 aZuidema J00aInfluence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.  a73-60 v343 a<p>In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.</p>  a0031-6970